Credit Suisse Group began coverage on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Tuesday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $27.00 price objective on the stock.
KURA has been the topic of several other research reports. Zacks Investment Research upgraded Kura Oncology from a hold rating to a buy rating and set a $19.00 price target on the stock in a research note on Saturday, May 30th. Deutsche Bank cut their price target on Kura Oncology from $28.00 to $24.00 and set a buy rating on the stock in a research note on Tuesday, May 19th. Barclays initiated coverage on Kura Oncology in a research note on Monday, May 4th. They set an overweight rating and a $24.00 price target on the stock. Wedbush cut their price target on Kura Oncology from $30.00 to $28.00 and set an outperform rating on the stock in a research note on Wednesday, May 6th. Finally, BidaskClub raised Kura Oncology from a sell rating to a hold rating in a research report on Wednesday, June 17th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $24.78.
KURA stock opened at $17.88 on Tuesday. The company has a quick ratio of 15.19, a current ratio of 15.19 and a debt-to-equity ratio of 0.03. The business’s fifty day simple moving average is $17.05 and its two-hundred day simple moving average is $13.19. Kura Oncology has a twelve month low of $6.35 and a twelve month high of $21.15. The firm has a market cap of $826.49 million, a price-to-earnings ratio of -11.54 and a beta of 2.29.
A number of hedge funds and other institutional investors have recently made changes to their positions in KURA. Ikarian Capital LLC purchased a new stake in Kura Oncology during the first quarter worth $7,560,000. Goldman Sachs Group Inc. boosted its holdings in Kura Oncology by 201.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 653,852 shares of the company’s stock worth $8,991,000 after buying an additional 437,182 shares in the last quarter. Prosight Management LP boosted its holdings in Kura Oncology by 40.0% during the first quarter. Prosight Management LP now owns 1,450,000 shares of the company’s stock worth $14,428,000 after buying an additional 414,000 shares in the last quarter. AXA purchased a new stake in Kura Oncology during the first quarter worth $3,244,000. Finally, Aviva PLC purchased a new stake in Kura Oncology during the first quarter worth $2,473,000. 87.35% of the stock is currently owned by hedge funds and other institutional investors.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Read More: How Short Selling Works
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.